Sugammadex - A short review and clinical recommendations for the cardiac anesthesiologist
| Autor: | Goetz Geldner, Dirk Nauheimer, Thomas M. Hemmerling, Cédrick Zaouter |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system Neuromuscular transmission review Sugammadex law.invention lcsh:RD78.3-87.3 Clinical Trials Phase II as Topic law medicine Humans Anesthesia Drug Interactions Cardiac Surgical Procedures Rocuronium Clinical Trials as Topic Neuromuscular Blockade Clinical Trials Phase I as Topic Dose-Response Relationship Drug business.industry General Medicine Cardiac surgery Intensive care unit Clinical trial Anesthesiology and Pain Medicine Clinical Trials Phase III as Topic lcsh:Anesthesiology lcsh:RC666-701 Pharmacodynamics sugammadex Cardiology and Cardiovascular Medicine business gamma-Cyclodextrins medicine.drug |
| Zdroj: | Annals of Cardiac Anaesthesia, Vol 13, Iss 3, Pp 206-216 (2010) |
| ISSN: | 0974-5181 0971-9784 |
| Popis: | This review outlines the basic pharmacodynamic and pharmacokinetic properties of sugammadex for the cardiac anesthesiologist. It describes the different clinical scenarios when sugammadex can be used during cardiac surgery and gives clinical recommendations. Sugammadex is a unique reversal drug that binds a chemical complex with rocuronium and vecuronium, by which the neuromuscular blockade is quickly reversed. It is free of any clinical side-effects and doses of 2 mg/kg or more reliably reverse neuromuscular blockade within 5-15 min, depending on the depth of the neuromuscular blockade. Doses below 2 mg/kg should be avoided at any time because of the inherent risk of recurarization. Sugammadex should not replace good clinical practice - titration of neuromuscular blocking drugs to clinical needs and objective monitoring of neuromuscular blockade in the operating room or intensive care unit. Neuromuscular transmission should be determined in all patients before sugammadex is considered and 5 min after its administration to ensure that extubation is performed with normal neuromuscular transmission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|